跳至主要内容
临床试验/NCT01451190
NCT01451190已完成2 期

A Multi-center, Phase 2 Study of Ji Gami(TM) CN That Evaluates the Efficacy and Safety of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells Into the Hair Loss Area of the Scalp of Subjects

Aderans Research Institute13 个研究点 分布在 1 个国家目标入组 88 人开始时间: 2011年7月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
88
试验地点
13
主要终点
Change from baseline in hair number

研究概览

简要总结

Evaluate the ability of injections of Ji Gami(TM) CN to induce hair growth in male and female subjects with hair loss.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female volunteers 18 to 65 years old, inclusive
  • Hair loss consistent with ≥ Grade III-Vertex, IV, VA, V, and VI, based on Norwood-Hamilton Scale providing there is bridging of hair in the anterior edge of the vertex circle.
  • Able to provide informed consent after risks and benefits of the study have been explained.
  • Be willing to undergo all study procedures.
  • Ability to communicate effectively with study personnel.
  • Have no clinically significant disease or abnormal laboratory evaluations taken at the screening visit.
  • Agree to abstain from use of any hair growth affecting oral or topical medication including over the counter and herbal medications, minoxidil, finasteride or dutasteride during the course of this study.

排除标准

  • Known sensitivity to DMEM/F-12 or any component of the study material.
  • Known hypersensitivity to clindamycin hydrochloride, amphotericin B or streptomycin sulfate.
  • Subjects who have used minoxidil or any oral or topical medication including over the counter and herbal medications for the treatment of hair loss within 6 months of study screening, or finasteride or dutasteride within 12 months of study screening.
  • A history of drug or alcohol abuse within 1 year of study enrollment.
  • Participation in any other investigational study within 30 days or six half lives of its biologic activity, whichever is longer, before the scalp excision visit(s), and during the time enrolled in this study.
  • Clinically significant medical or psychiatric illness currently or within 30 days of study screening as determined by the investigator.
  • Clinically significant abnormal laboratory parameters.
  • A positive result at screening for human immunodeficiency virus (HIV 1 or 2), Hepatitis B or C, HTLV I/II.
  • Clinically significant dermatologic condition in donation or study areas.
  • Prior surgery in the donor or study areas.
  • Insufficient hair or scarring in the donor area that might impact cell growth.
  • Any disease or condition (medical or surgical) that, in the opinion of the investigator, might compromise hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, or central nervous system function; or any condition that would place the subject at increased risk.

结局指标

主要结局

Change from baseline in hair number

时间窗: 51 weeks post-injection

Change from baseline in hair width

时间窗: 51 weeks post-injection

Time course of any treatment benefit

时间窗: 51 weeks post-injection

次要结局

未报告次要终点

研究者

发起方
Aderans Research Institute
申办方类型
Industry
责任方
Sponsor

研究点 (13)

Loading locations...

相似试验